OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC

Abstract EN

Background.

Osteopontin (OPN) is associated with prognosis of patients with non-small-cell lung cancer (NSCLC).

However, little is known about the association between OPN gene polymorphism and the chemotherapy response in NSCLC patients.

Methods.

A total of 497 patients with inoperable advanced stage of NSCLC (stages III B and IV NSCLC) were enrolled.

All patients had received platinum-based chemotherapy.

OPN gene polymorphisms at 156 GG/G, 443 C/T, and −66T/G were determined.

Results.

The genotypes and allele frequency of −443C>T were significantly different between the responders and nonresponders.

Responders had a markedly higher frequency of −443TT genotype than responders (40.71% versus 19.09%, P<0.001).

With CC as reference, the TT genotype carriers had a higher chance to be well responders (adjusted OR=4.43, 95% CI: 2.60–7.53, adjusted P<0.001).

The median overall survival time for patients with −443CC, −443CT, and −443TT genotype carriers was significantly different.

Multivariate Cox proportional hazards regression models showed that OPN −443C>T gene polymorphisms were closely correlated to poor NSCLC prognosis.

Conclusion.

OPN −443C>T gene polymorphism may be used as a molecular marker to predict the treatment response to chemotherapy in advanced NSCLC patients.